Skip to Content

Grifols SA ADR GIKLY

Morningstar Rating
$5.90 +0.30 (5.36%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

GIKLY is trading at a 37% discount.
Price
$5.87
Fair Value
$2.18
Uncertainty
High
1-Star Price
$31.35
5-Star Price
$8.90
Economic Moat
Pjcwlj
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GIKLY is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$5.60
Day Range
$5.906.09
52-Week Range
$4.198.70
Bid/Ask
$5.76 / $6.13
Market Cap
$8.01 Bil
Volume/Avg
694 / 5,309

Key Statistics

Price/Earnings (Normalized)
49.50
Price/Sales
1.09
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's biopharma business contributed 83% of sales in 2022. Grifols also has smaller segments including diagnostics and biosupplies. Diagnostics is roughly 10% of revenue following the Biotest acquisition.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Mid Core
Total Number of Employees
26,314

Competitors

Valuation

Metric
GIKLY
CSL
PFE
Price/Earnings (Normalized)
49.5029.199.45
Price/Book Value
1.175.421.58
Price/Sales
1.096.492.65
Price/Cash Flow
33.887.95
Price/Earnings
GIKLY
CSL
PFE

Financial Strength

Metric
GIKLY
CSL
PFE
Quick Ratio
0.720.951.90
Current Ratio
2.482.152.38
Interest Coverage
1.287.216.05
Quick Ratio
GIKLY
CSL
PFE

Profitability

Metric
GIKLY
CSL
PFE
Return on Assets (Normalized)
1.17%7.37%8.04%
Return on Equity (Normalized)
4.22%16.50%16.96%
Return on Invested Capital (Normalized)
3.28%10.05%11.79%
Return on Assets
GIKLY
CSL
PFE
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - General Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
LLY
Eli Lilly and CoSqd$708.7 Bil
JNJ
Johnson & JohnsonGmt$382.2 Bil
MRK
Merck & Co IncZbkfj$324.7 Bil
ABBV
AbbVie IncChjw$309.4 Bil
RHHBY
Roche Holding AG ADRPlvs$210.5 Bil
NVS
Novartis AG ADRHtwg$208.7 Bil
AZN
AstraZeneca PLC ADRVpkw$197.7 Bil
PFE
Pfizer IncVbs$156.2 Bil
AMGN
Amgen IncGpnm$151.9 Bil
SNY
Sanofi SA ADRZtqw$117.9 Bil

Sponsor Center